Aileron Therapeutics
February 26, 2024
Respiratory
Aileron is developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions. With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases. Lung Therapeutics’ lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).
)
){kind=logo}
)
){kind=logo}
){kind=logo}